The stock of Omeros Corporation (NASDAQ:OMER) hit a new 52-week low and has $6.74 target or 14.00% below today’s $7.84 share price. The 6 months bearish chart indicates high risk for the $303.67M company. The 1-year low was reported on Oct, 13 by Barchart.com. If the $6.74 price target is reached, the company will be worth $42.51M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 420,466 shares traded hands or 37.50% up from the average. Omeros Corporation (NASDAQ:OMER) has declined 49.02% since March 10, 2016 and is downtrending. It has underperformed by 56.54% the S&P500.
Analysts await Omeros Corporation (NASDAQ:OMER) to report earnings on November, 14. They expect $-0.30 earnings per share, up 34.78% or $0.16 from last year’s $-0.46 per share. After $-0.24 actual earnings per share reported by Omeros Corporation for the previous quarter, Wall Street now forecasts 25.00% negative EPS growth.
Omeros Corporation (NASDAQ:OMER) Ratings Coverage
Out of 6 analysts covering Omeros (NASDAQ:OMER), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Omeros has been the topic of 10 analyst reports since August 10, 2015 according to StockzIntelligence Inc. As per Friday, June 3, the company rating was initiated by Cantor Fitzgerald. The stock has “Strong Buy” rating given by WBB Securities on Tuesday, August 18. Cowen & Co maintained the stock with “Outperform” rating in Tuesday, August 18 report. On Wednesday, November 11 the stock rating was maintained by Needham with “Buy”. The rating was maintained by Needham with “Buy” on Monday, August 31. On Monday, August 10 the stock rating was initiated by Roth Capital with “Buy”. The rating was initiated by TH Capital with “Buy” on Monday, August 10.
According to Zacks Investment Research, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.”
Insitutional Activity: The institutional sentiment decreased to 0.77 in 2016 Q2. Its down 0.21, from 0.98 in 2016Q1. The ratio dived, as 15 funds sold all Omeros Corporation shares owned while 32 reduced positions. 13 funds bought stakes while 23 increased positions. They now own 19.91 million shares or 14.90% more from 17.33 million shares in 2016Q1.
Mackenzie Fin has 0.01% invested in the company for 114,400 shares. Next Financial Grp holds 0% or 1,000 shares in its portfolio. Voya Investment Mngmt Limited Liability Company, a Georgia-based fund reported 15,996 shares. Moreover, Brown Advisory has 0.02% invested in Omeros Corporation (NASDAQ:OMER) for 543,763 shares. Tiaa Cref Inv Mgmt holds 117,381 shares or 0% of its portfolio. The Missouri-based Stifel Financial Corp has invested 0.02% in Omeros Corporation (NASDAQ:OMER). Rtw Invests Limited Liability Corp, a New York-based fund reported 526,788 shares. Royal Commercial Bank Of Canada last reported 100 shares in the company. Proshare Advsr Limited Liability Company holds 0% or 33,656 shares in its portfolio. Teachers Advsr accumulated 0% or 57,987 shares. Deutsche Retail Bank Ag last reported 11,910 shares in the company. Fincl Grp accumulated 0.58% or 715,101 shares. Moreover, Mufg Americas Holding Corporation has 0% invested in Omeros Corporation (NASDAQ:OMER) for 804 shares. Brighton Jones has invested 0.02% of its portfolio in Omeros Corporation (NASDAQ:OMER). Davenport & Ltd Liability Corporation reported 59,200 shares or 0% of all its holdings.
Insider Transactions: Since April 15, 2016, the stock had 0 buys, and 5 selling transactions for $732,521 net activity. Kelbon Marcia S. also sold $158,057 worth of Omeros Corporation (NASDAQ:OMER) on Monday, May 16. On Friday, August 12 the insider Cable Thomas J. sold $34,557.
More notable recent Omeros Corporation (NASDAQ:OMER) news were published by: Fool.com which released: “Why Omeros Corporation’s Stock Dropped Today” on August 11, 2016, also Prnewswire.com with their article: “Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European …” published on July 28, 2016, Fool.com published: “Is This The Reason That Omeros Corporation Fell 17.7% in April?” on May 06, 2016. More interesting news about Omeros Corporation (NASDAQ:OMER) were released by: Fool.com and their article: “Why Omeros Corporation Dropped 12% in February” published on March 08, 2016 as well as Businesswire.com‘s news article titled: “Omeros Corporation Announces Completion of Patient Enrollment in Pediatric …” with publication date: June 29, 2016.
OMER Company Profile
Omeros Corporation, incorporated on June 16, 1994, is a biopharmaceutical company. The Firm is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is launched in the United States for use during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from the Company’s PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. The Company’s PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.